Defective RNA Processing and Protein Folding May Promote ALS, Lab Study Suggests

Defects in RNA processing and transport, as well as protein folding, may contribute to amyotrophic lateral sclerosis (ALS) pathology, according to the results of recent research. The study, “Altered nucleocytoplasmic proteome and transcriptome distributions in an in vitro model of amyotrophic lateral sclerosis,” was published in the journal PLOS…

College students from the Oklahoma Christian University are helping an ALS sufferer communicate with his wife again. Sixty-four-year-old Carl Phelps from Oklahoma was diagnosed with bulbar onset amyotrophic lateral sclerosis (ALS) in April 2015. The disease’s first symptoms appear in the mouth and many patients experience problems talking, eating and…

Between 1943 and 1979, miners around the world were encouraged (and in some cases forced) to inhale aluminum dust called McIntyre Powder, believing that the substance would help protect their lungs. However, a health agency in Ontario has found an alarming link between McIntyre Powder and amyotrophic lateral sclerosis (ALS).

Pfizer and AbbVie are pumping $10 million into Aquinnah Pharmaceuticals‘ effort to develop a revolutionary approach to treating neurodegenerative diseases — one that could arrest, or even reverse, the progression of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s and other conditions. Takeda Pharmaceuticals invested $5 million in Aquinnah’s program in December 2015.

May is ALS Awareness Month and the ALS community is seeking the help of individuals willing to participate, advocate and donate to advance the fight toward a world free of amyotrophic lateral sclerosis, commonly known as “Lou Gehrig’s Disease.” The ALS Association is a national non-profit organization dedicated to building…

Biohaven Pharmaceuticals is pushing hard for regulatory approval and development of its two investigational drugs for amyotrophic lateral sclerosis (ALS): BHV-0223, a sublingual form of Rilutek (riluzole), and BHV-4157, a compound that modulates the neurotransmitter glutamate. After more than 20 years, Rilutek remains the only approved treatment for people with…

Amyotrophic lateral sclerosis (ALS) is a disease that causes the degeneration of motor neurons, eventually leading to a loss of movement and patients being unable to breathe without assistance. We’ve put together a list of fast facts about ALS with help from the National Institute of Neurological Disorders and…

More amyotrophic lateral sclerosis (ALS) patients survived among those who completed a Phase 2 trial of MediciNova’s Ibudilast (MN-166), compared to those who dropped out of the study, according to an exploratory interim analysis. But the data, presented at the American Academy of Neurology (AAN) 2017 Annual Meeting…

  In this University of California TV video, Dr. Geoffrey Sheean from the School of Medicine, UC San Diego, talks about the early stages of amyotrophic lateral sclerosis (ALS). MORE: Explaining the progression of ALS Dr. Sheean explains that often the first signs of the…

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the deterioration of muscles in the body, leading to loss of movement, an inability to speak and swallow, and eventually, breathe. According to medscape.com, the rate at which muscle deterioration occurs will differ from patient to…